Voya Investment Management LLC boosted its position in Amgen, Inc. (NASDAQ:AMGN) by 6.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 482,923 shares of the medical research company’s stock after purchasing an additional 27,670 shares during the period. Voya Investment Management LLC owned approximately 0.07% of Amgen worth $83,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. PGGM Investments lifted its stake in Amgen by 2.3% in the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after purchasing an additional 15,059 shares during the last quarter. Shelton Capital Management lifted its stake in Amgen by 82.7% in the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after purchasing an additional 49,354 shares during the last quarter. Greylin Investment Mangement Inc. lifted its stake in Amgen by 466.9% in the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after purchasing an additional 11,555 shares during the last quarter. Kelman Lazarov Inc. increased its position in shares of Amgen by 8.2% during the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock worth $272,000 after acquiring an additional 120 shares during the period. Finally, Osborne Partners Capital Management LLC increased its position in shares of Amgen by 0.5% during the second quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock worth $2,932,000 after acquiring an additional 91 shares during the period. 78.38% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have recently commented on AMGN. Credit Suisse Group reaffirmed a “neutral” rating and set a $186.00 target price (up from $177.00) on shares of Amgen in a research report on Friday, September 29th. Royal Bank Of Canada began coverage on shares of Amgen in a research report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 target price on the stock. Mizuho reaffirmed a “buy” rating and set a $183.00 target price (down from $195.00) on shares of Amgen in a research report on Monday, August 21st. Morgan Stanley reduced their target price on shares of Amgen from $196.00 to $193.00 and set an “overweight” rating on the stock in a research report on Thursday, October 26th. Finally, Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $199.00 target price on the stock in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $190.22.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $175.41 on Friday. The firm has a market cap of $126,279.41, a P/E ratio of 13.83, a price-to-earnings-growth ratio of 2.52 and a beta of 1.36. Amgen, Inc. has a one year low of $141.00 and a one year high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. Amgen’s revenue was down .7% compared to the same quarter last year. During the same period last year, the firm earned $3.02 earnings per share. equities research analysts anticipate that Amgen, Inc. will post 12.66 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, December 8th. Shareholders of record on Friday, November 17th were paid a $1.15 dividend. The ex-dividend date was Thursday, November 16th. This represents a $4.60 annualized dividend and a yield of 2.62%. Amgen’s dividend payout ratio (DPR) is 41.63%.
Amgen announced that its Board of Directors has authorized a stock buyback plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: This article was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2017/12/09/voya-investment-management-llc-has-83-18-million-holdings-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.